 |
2020 News Releases
Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
LOS ANGELES, Calif., May 6, 2020 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, will provide an overview of the Company at 3:40 p.m. EDT on Wednesday, May 13, at the
BofA Securities Health Care Conference 2020. The conference will be held in a virtual meeting format.
A live webcast of the presentation will be available on the Company's website
at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30
days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licenses the global
development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous)
and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the
extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast
cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in
combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-
positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic
setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the
extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-
overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant
trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
Contact:
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
# # # # #
Back to 2020 News Releases
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
